Loading
SI
Soliton, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Remeditex Ventures LLC, was filed 01 Jul 2020.
Soliton, Inc.: what insiders have been doing
This page follows insider dealings at Soliton, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Nothing new has been filed by managers of Soliton, Inc. in twelve months, the latest record being from 17 December 2021.
The full history, which starts in 2019, counts 3 purchases against no sales.
For comparison within the same sector, see the insider buying recorded at Xenon Pharmaceuticals Inc. and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
9
Thresholds
n/a
Buy Volume
€889,993
3 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2020FY ended December 2020 · cache
Income statement
Net income-US$12.5M
Last declaration on 17 December 2021
Declarations9 total
175,000 shares@ US$22.6039.9% of flowCommon StockSEC:0001548187-21-000073:1
60,000 shares@ US$22.60100.0% of flowCommon StockSEC:0001548187-21-000072:0
263,440 shares@ US$22.60100.0% of flowCommon StockSEC:0001548187-21-000073:0
9,214,277 shares@ US$22.60100.0% of flowCommon StockSEC:0001548187-21-000080:0
425,000 shares@ US$22.60100.0% of flowCommon StockSEC:0001548187-21-000079:0
80,000 shares@ US$22.60100.0% of flowCommon StockSEC:0001548187-21-000081:0
120,481 shares@ US$8.300.5% of flowCommon StockSEC:0001548187-20-000086:0
Canonical exit: 28 Sept 2020 (T+90)
155,280 sharesCommon StockSEC:0001437749-19-020084:0
Canonical exit: 9 Jan 2020 (T+90)
357,143 sharesCommon StockSEC:0001437749-19-012300:0
Canonical exit: 17 Sept 2019 (T+90)
9 of 9 declarations
About Soliton, Inc.
Soliton, Inc. (ticker: SOLY) was a United States medical device company that traded on the NASDAQ market. Founded in 2012 and incorporated in Delaware, the company developed a proprietary technology platform licensed from The University of Texas on behalf of the MD Anderson Cancer Center. Its core business sat within medical aesthetics and non-invasive skin-treatment technologies, with a particular emphasis on acoustic shockwave-based applications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1548187/000154818721000015/soly-20201231.htm?utm_source=openai))
Operationally, Soliton centered its development efforts on the RAP, or Rapid Acoustic Pulse, device. The company described RAP as a tool intended to help enable more efficient multi-pass laser treatments in a single office visit, and its public disclosures highlighted its use in aesthetic indications such as cellulite and fibrotic scars. In other words, Soliton was primarily a product-development medtech company: its value proposition depended on a differentiated device, intellectual property protection, and eventual regulatory clearance and commercialization. ([globenewswire.com](https://www.globenewswire.com/news-release/2018/11/29/1658848/0/en/Soliton-Inc-Developer-of-Patented-Shockwave-Technology-Prices-and-Launches-its-Nasdaq-Initial-Public-Offering.html?utm_source=openai))
Read moreShow less
From a competitive standpoint, Soliton operated in a crowded aesthetic-medical-device market populated by larger, better-capitalized players with broader product portfolios and established distribution footprints. Soliton’s strategy was to compete through technical differentiation rather than scale. For investors, that meant a classic small-cap medical technology risk profile: high dependence on clinical adoption, regulatory milestones, and access to funding, with execution risk remaining elevated until commercialization is proven. Its SEC filings explicitly noted the possibility that additional capital may be required to continue executing the business plan. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1548187/000154818721000015/soly-20201231.htm?utm_source=openai))
The company’s historical headquarters were in Houston, Texas, and its communications reflected a development-stage organization focused on advancing clinical programs, protecting brand and product assets, and moving toward broader market acceptance. The business was best understood as a niche medtech story rather than a diversified healthcare platform. For French-speaking investors, the important takeaway is that SOLY was a U.S.-listed innovation company in the health and medical-device space, not a mature pharmaceutical or hospital-services group. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1548187/000154818721000015/soly-20201231.htm?utm_source=openai))
Recent public records show insider transactions filed on SEC Form 4, confirming ongoing reporting activity by executives and directors during the period when the stock was still listed. The broader public record also indicates that Soliton later ceased to trade as an independent listed issuer under the SOLY symbol, which is essential context when interpreting any legacy references in datasets, filings, or insider-transaction feeds. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1548187/000154818721000081/0001548187-21-000081-index.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
